About Chimerix
Chimerix is a company based in Durham (United Kingdom) founded in 2002 was acquired by Jazz Pharmaceuticals in March 2025.. Chimerix has raised $95.23 million across 5 funding rounds from investors including Jazz Pharmaceuticals, New Leaf Venture Partners and Frazier Healthcare Partners. The company has 72 employees as of December 31, 2023. Chimerix has completed 1 acquisition, including Oncoceutics. Chimerix offers products and services including TEMBEXA, ONC201, and ONC206. Chimerix operates in a competitive market with competitors including Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Alnylam, among others.
- Headquarter Durham, United Kingdom
- Employees 72 as on 31 Dec, 2023
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$30 K-100as on Dec 31, 2023
-
Net Profit
$-88.39 M-8as on Dec 31, 2024
-
EBITDA
$-96.57 M-4as on Dec 31, 2024
-
Total Equity Funding
$95.23 M (USD)
in 5 rounds
-
Latest Funding Round
$122 M (USD), Post-IPO
Nov 01, 2014
-
Investors
Jazz Pharmaceuticals
& 9 more
-
Employee Count
72
as on Dec 31, 2023
- Investments & Acquisitions
-
Acquired by
Jazz Pharmaceuticals
(Mar 05, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Chimerix
Chimerix offers a comprehensive portfolio of products and services, including TEMBEXA, ONC201, and ONC206. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats serious viral diseases through targeted medication.
Addresses gliomas and brain tumors via innovative therapy.
Targets central nervous system tumors for improved outcomes.
Unlock access to complete
Funding Insights of Chimerix
Chimerix has successfully raised a total of $95.23M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $122 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $122.0M
-
First Round
First Round
(04 Nov 2004)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2014 | Amount | Post-IPO - Chimerix | Valuation |
investors |
|
| Feb, 2011 | Amount | Series F - Chimerix | Valuation | New Leaf Venture Partners , Pappas Capital | |
| Jul, 2009 | Amount | Series E - Chimerix | Valuation | Alta Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Chimerix
Chimerix has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Jazz Pharmaceuticals, New Leaf Venture Partners and Frazier Healthcare Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life sciences are managed.
|
Founded Year | Domain | Location | |
|
VC firm focusing on life science sector
|
Founded Year | Domain | Location | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Chimerix
Chimerix has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Oncoceutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Clinical-stage drug development company focused on oncology
|
2009 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Chimerix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Chimerix Comparisons
Competitors of Chimerix
Chimerix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Alnylam, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Chimerix
Frequently Asked Questions about Chimerix
When was Chimerix founded?
Chimerix was founded in 2002 and raised its 1st funding round 2 years after it was founded.
Where is Chimerix located?
Chimerix is headquartered in Durham, United Kingdom.
Is Chimerix a funded company?
Chimerix is a funded company, having raised a total of $95.23M across 5 funding rounds to date. The company's 1st funding round was a Series E of $16.13M, raised on Nov 04, 2004.
How many employees does Chimerix have?
As of Dec 31, 2023, the latest employee count at Chimerix is 72.
What is the annual revenue of Chimerix?
Annual revenue of Chimerix is $30K as on Dec 31, 2023.
What does Chimerix do?
The company was founded in 2002 in Durham, United Kingdom, within the biotechnology sector. Antiviral oral therapeutics are developed, with a pipeline that includes Brincidofovir for smallpox treatment, ONC201 for mutant glioma, DSTAT for acute myeloid leukemia, and ONC206 for solid tumors. Quality of life is improved for patients across transplant, oncology, acute care, and global health settings through these operations.
Who are the top competitors of Chimerix?
Chimerix's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Chimerix offer?
Chimerix offers TEMBEXA, ONC201, and ONC206.
How many acquisitions has Chimerix made?
Chimerix has made 1 acquisition, including Oncoceutics.
Who are Chimerix's investors?
Chimerix has 10 investors. Key investors include Jazz Pharmaceuticals, New Leaf Venture Partners, Frazier Healthcare Partners, Canaan, and Pappas Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.